表紙
市場調查報告書

念珠菌症治療藥市場 - 成長,趨勢,及預測(2019年 - 2024年)

Candidiasis Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 871440
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
Back to Top
念珠菌症治療藥市場 - 成長,趨勢,及預測(2019年 - 2024年) Candidiasis Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年05月01日內容資訊: 英文 115 Pages
簡介

念珠菌症治療藥市場,由於患念珠菌症感染疾病的患者數增加,及對念珠菌症感染疾病的認識高漲等要素,預計急速擴大。

本報告提供全球念珠菌症治療藥市場的相關調查,市場概況和成長要素、阻礙因素,各投藥途徑、治療藥類型、解剖學類型、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊彙整。

目錄

第1章 簡介

  • 研究成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 感染了念珠菌症的患者數增加
    • 念珠菌症感染疾病的認識高漲
  • 市場阻礙因素
    • 替代治療的利用可能性
    • 與中藥及替代療法的競爭
  • 波特五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業的競爭

第5章 市場區隔

  • 各投藥途徑
    • 注射
    • 軟膏
    • 口服
  • 各治療藥類型
    • Polyenes
    • Azole
    • Echinocandins
    • 其他
  • 各解剖學類型
    • 口腔念珠菌症
    • 陰道陰道念珠菌症
    • 皮膚念珠菌症
    • 侵入性念珠菌症
    • 全身性念珠菌症
  • 各流通管道
    • 醫院
    • 診療所
    • 零售藥局
    • 藥妝店
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Basilea Pharmaceuticals
    • Astellas
    • Ferrer Internacional
    • Pacgen Biopharmaceuticals
    • NovaDigm Therapeutics
    • Pevion Biotech
    • Amplyx Pharmaceuticals, Inc.
    • Biomar Microbial Technologies
    • Cidara Therapeutics, Inc.
    • Novabiotics Limited

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52984

Market Overview

The candidiasis therapeutics market is expected to witness rapid growth due to the increase in the number of patients affected by candidiasis infection, increasing the susceptible immune compromised patient pool and growing awareness for candidiasis infection.

There has been an increase in the number of patients affected by candidiasis infection in the developing markets that are expected to boost the overall market growth over the forecast period. The Center for Disease Control and Prevention (CDC) estimates that approximately 46,000 cases of healthcare-associated invasive candidiasis occur each year, in the United States. CDC reports that the 30-day all-cause (crude) mortality among people with candidemia is approximately 30%. However, as people who develop invasive candidiasis typically have pre-medical conditions, it is generally ambiguous to determine the proportion of deaths directly attributable to the infection. This increase in the number of patients has helped in spurring the growth of the overall market. The increasing of urbanization and rising hygiene awareness in developing countries also helps in the growth of the market.

Scope of the Report

As per the scope of the report, candidiasis is commonly a fungal infection that affects men and women both of all age groups. It is also known as candidosis, moniliasis, and oidiomycosis. The effects of this infection are seen on a dermal, internal and systemic level wherein it is known as candidemia or intestinal thrush. The market is dynamic due to the widespread occurrence of this disease. The major drug classes for treatment include azoles, polyenes, and echinocandins.

Key Market Trends

Systemic Candidiasis is Anticipated to be the Dominant Segment in Anatomy Type During the Forecast Period

The market for systemic candidiasis is found to be driven by the increase in the susceptible immune compromised patient pool. Thrush occurs in approximately 2-5 percent of healthy newborn and affects them mainly during their first year of life. Over 1 million adult women and adolescent girls in the US develop vaginal yeast infections each year. Therefore the high incidence of candidiasis is expected to remain a major driver for the growth of the market during the forecast period.

North America Region Holds the Largest Market Share of Candidiasis Therapeutics Market

Due to the high investment in healthcare and awareness of diseases, the North American segment of the market studied is estimated to account for the highest market share. The candidiasis disease is found growing rapidly in the US and is not restricted to any particular region. It has also been found that the North America and Europe region has been accountable for the largest markets revenue share due to a higher awareness of the disease amongst individuals and also the availability of better treatment. Hence all these factors are associated with the growth of the market.

Competitive Landscape

The major companies present in the market are found focusing on product innovations, expansions, finding new markets or innovating their core competency to expand their individual market share.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Number of Patients Affected by Candidiasis Infection
    • 4.2.2 Growing Awareness for Candidiasis Infection
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatments
    • 4.3.2 Narrow Pipeline Molecules
    • 4.3.3 Competition from Herbal Medicines and Alternate Therapies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Route of Administration
    • 5.1.1 Injection
    • 5.1.2 Ointment
    • 5.1.3 Oral
  • 5.2 By Drug Type
    • 5.2.1 Polyene
    • 5.2.2 Azole
    • 5.2.3 Echinocandin
    • 5.2.4 Others
  • 5.3 By Anatomy Type
    • 5.3.1 Oral Candidiasis
    • 5.3.2 Vulvovaginal Candidiasis
    • 5.3.3 Cutaneous Candidiasis
    • 5.3.4 Invasive Candidiasis
    • 5.3.5 Systemic Candidiasis
  • 5.4 By Distribution Channel
    • 5.4.1 Hospitals
    • 5.4.2 Clinics
    • 5.4.3 Retail Pharmacies
    • 5.4.4 Drug Stores
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 US
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 UK
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Basilea Pharmaceuticals
    • 6.1.2 Astellas
    • 6.1.3 Ferrer Internacional
    • 6.1.4 Pacgen Biopharmaceuticals
    • 6.1.5 NovaDigm Therapeutics
    • 6.1.6 Pevion Biotech
    • 6.1.7 Amplyx Pharmaceuticals, Inc.
    • 6.1.8 Biomar Microbial Technologies
    • 6.1.9 Cidara Therapeutics, Inc.
    • 6.1.10 Novabiotics Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top